



Organisation
of European
Cancer Institutes

In collaboration with



Maria Skłodowska-Curie
**National Research
Institute of Oncology**

Oncology Days

 **ECI 48**

**WORKING TOGETHER TO IMPROVE
QUALITY AND REDUCE INEQUALITIES**

WARSAW 2026

**GENERAL ASSEMBLY AND
SCIENTIFIC PROGRAMME**

17 - 19 June 2026



**PRELIMINARY
ANNOUNCEMENT**

President's Welcome

*Dear OECI Members,
Dear Colleagues and Friends*

The OECI Oncology Days represent a privileged moment for meeting, reflection, and exchange among our members, an opportunity to share achievements, discuss emerging challenges, and jointly define future priorities in the fight against cancer.

Warsaw, a city symbolizing rebirth, innovation, and resilience, offers an ideal setting to reflect on what OECI has accomplished in recent years and how we can continue to grow as a European community of cancer research and care.

For me, this meeting holds a special meaning, as it marks the conclusion of my term as President of OECI, allowing me to look back with gratitude and pride on the journey we have shared together.

Over the past three years, we have made significant progress in strengthening OECI's role as a network of excellence and a driver of European integration. Among the results I would like to highlight:

- our participation, as leaders and/or beneficiaries, in several European projects that will undoubtedly shape the future of our Organisation, with the commitment to pursue the initiatives undertaken, which will offer concrete opportunities to improve therapeutic options and the quality of life for our patients;
- the revision of standards and the expansion of the OECI Accreditation and Designation Programme, which today involves more than 60% of our Members in Europe and beyond, helping to spread a shared culture of quality and continuous improvement;
- the launch of new training and networking initiatives aimed at promoting collaboration among young researchers, clinicians, and managers of cancer centres;
- our efforts to strengthen the translational and interdisciplinary dimensions of cancer research, encouraging an increasingly integrated model of patient care and scientific innovation;
- the expansion of OECI's international dimension, with new partnerships and exchanges that have enabled us to share experiences and expertise on a global scale, setting a model to be followed in other continents.

All this would not have been possible without the dedication, competence, and vision of our Members, who represent the true strength of OECI:

To each of you, I express my sincerest gratitude

As my term comes to an end, I also wish to share with you my determination to continue working actively with OECI, focusing particularly on the development of international relations. I am deeply convinced that the future of our Organisation lies in its ability to build bridges between disciplines, between centres, between countries, and between continents.

The Oncology Days 2026 will therefore represent not only an opportunity to celebrate our achievements, but also to renew our commitment to a more cohesive, inclusive, and forward-looking network.

Although European institutions increasingly recognize OECI as an authoritative interlocutor in shaping cancer control policies, the next presidency will be called upon to further strengthen dialogue with both national and European authorities.

I am confident that the new OECI Presidency, under the leadership of Professor Iwona Lugowska, will continue and strengthen the path we have embarked upon, giving new impetus to the process of integrating the activities of Europe's most prestigious cancer institutes, and extending OECI's objectives beyond European borders.

I therefore hope that the OECI Oncology Days 2026 will provide a constructive dialogue, mutual inspiration, and renewed energy in our shared goal: to ensure that cancer patients receive treatments that are ever more effective, personalised, and respectful of the dignity of each individual.

To conclude, we are immensely grateful to the Maria Skłodowska-Curie National Research Institute of Oncology for kindly offering to host this edition of the OECI Oncology Days. We hope you will enjoy the OECI Oncology Days 2026 in Warsaw, an event that celebrates the 48th Anniversary of the OECI Foundation.



Giovanni Apolone
OECI President

Giovanni Apolone

The OECI Board

 President Chairperson OECI EU Affairs Giovanni Apolone Italy	
 Vice-President Iwona Ługowska Poland	 Executive Secretary Júlio Manuel Maia de Oliveira Portugal
 Treasurer Alfredo Budillon Italy	 Elected Member ECO Representative Maja Čemažar Slovenia
 Elected Member OECI Young Board Per Anders Sandström Sweden	 Elected Member Chairperson Gender Equality Jacqueline M.L. Stouthard The Netherlands
 Elected Member Olga Balaoura Greece	 Elected Member Christian Brands Germany
 Elected Member Steven le Gouill France	 Elected Member Josep Tabernero Caturla Spain

Co-opted Members to the OECI Board

 OECI General Manager Claudio Lombardo Belgium - Italy	 OECIWORLD Chairperson Thierry Philip Belgium - Italy
---	--

Accreditation and Designation Programme

 A&D Board Chairperson Jean-Benoît Burrión Belgium		 A&D Quality Director Simon Oberst Denmark
---	---	---

Working Groups

 Biobanks and Molecular Pathobiology WG Chairperson Olli Carpén Finland	 Cancer Outcomes Research WG Chairperson To be appointed
 Cancer Economics WG Chairperson Wim H. van Harten The Netherlands	 OECI for Patients Delia Nicoară Romania

OECI2026 ONCOLOGY DAYS

Welcome to the Oncology Days 2026!

I'm delighted to welcome you to Warsaw for the OECI Oncology Days 2026, hosted by the Maria Skłodowska-Curie National Research Institute of Oncology. It is a privilege for our Institute, the leading comprehensive cancer centre in Poland and a proud OECI member, to bring together the European oncology community in the very heart of Central Europe.

Warsaw, the city of Maria Skłodowska-Curie, embodies the spirit of resilience, innovation, and scientific discovery. Her legacy continues to inspire generations of researchers, clinicians, and innovators across the world. Hosting this year's Oncology Days in a city that bears her name is both a tribute to her groundbreaking discoveries and a reaffirmation of our shared commitment to excellence in cancer care, research, and prevention.

The OECI Oncology Days 2026 will focus on two crucial themes: new technologies in primary and secondary prevention, and national cancer networks. These topics reflect not only the strategic priorities of OECI but also our Institute's mission to translate scientific progress into real-world impact for patients. The sessions will showcase examples of European collaboration, from innovative digital prevention tools and genomics-driven screening to the creation of interconnected oncology networks that ensure quality, equity, and access to care.

Beyond the conference halls, we hope you will also take time to experience the unique atmosphere of Warsaw: a city rebuilt from the ashes, vibrant and forward-looking, where history meets modern science, and where determination transforms vision into achievement.


I wish you an inspiring, collaborative, and memorable meeting, one that strengthens our shared mission to improve cancer care across Europe.



Beata Jagielska

Institut Maria Skłodowska-Curie

The OECI Network




The OECI is a non-governmental Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping.

OECI presently comprises 177 Members, which include some of the most prominent European Comprehensive Cancer Centres.

Several major cancer centres from the Chile, Colombia, Jordan, Lebanon, Russian Federation, Tanzania, Turkey, Ukraine and Viet Nam are also members of the Organisation in order to benefit from the Accreditation and Designation Programme and to be involved in the activities promoted by the Working Groups.

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches to reduce mortality and to guarantee an equitable access to care to all cancer patients.

- OECI Member A&D certified Comprehensive Cancer Network
- ★ OECI Member A&D certified Comprehensive Cancer Centre
- ★ OECI Member A&D certified Cancer Centre
- ★ OECI Member in the A&D process
- OECI Member



The OECI membership

Algeria

- ★ Anti-Cancer Center Blida Algeria Specialized Hospital Control Against Cancer, Bida

Austria

- ★ Comprehensive Cancer Center Vienna, Vienna

Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Leuven Kankerinstituut (LKI), Leuven
- ★ Kortrijk Kankercentrum az groeninge, Kortrijk
- ★ Oncologisch Centrum UZBrussel, Brussels
- ★ UZ Gent Kankercentrum, Ghent
- ★ Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

Brazil

- ★ A.C. Camargo Cancer Centre, Sao Paulo

Bulgaria

- ★ Multiprofile Hospital for Active Treatment Heart and Brain Pleven, Pleven
- ★ Bulgarian Joint Cancer Network (BJCN), Varna

Chile

- ★ Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

China

- ★ Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou

Colombia

- ★ Instituto Nacional de Cancerología ESE, Bogota

Croatia

- ★ Klinika za tumor Klinički bolnički centar Sestre milosrdnice, Zagreb
- ★ Coalition of Associations for Healthcare, Zagreb

Cyprus

- ★ German Oncology Center (GOC), Limassol
- ★ Bank of Cyprus Oncology Centre, Nicosia

Czech Republic

- ★ Masarykův onkologický ústav, Brno
- ★ Fakultní nemocnice v Motole, Prague
- ★ Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- ★ Aarhus Universitetshospital, Aarhus
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Department of oncology Rigshospitalet, Copenhagen
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Department for cancer treatment, Herlev and Gentofte Hospital, Herlev
- ★ Odense Universitetshospital, Odense
- ★ Aalborg University Hospital, Aalborg
- ★ Zealand University Hospital, Køge

Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- ★ North Estonia Medical Centre, Tallinn
- ★ AS Ida-Tallinna Keskaigla, Tallinn

Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Syöpäkeskus Tampereen Yliopistollinen Sairaala, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu
- ★ Kansallinen syöpäkeskus FICAN, Helsinki

France

- ★ Association Toulousaine d'Oncologie Publique (ATOP), Toulouse
- ★ Centre Léon Bérard, Lyon
- ★ Gustave Roussy, Villejuif
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille

- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris
- ★ Cancer Institute AP-HP. Nord - Université Paris Cité, Paris
- ★ Institut du cancer Paris CARPEM AP-HP.Centre-Université Paris Cité, Paris
- ★ Centre François Baclesse, Caen
- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain
- ★ Centre de lutte contre le cancer Eugène Marquis, Rennes
- ★ Centre Henri Becquerel, Rouen
- ★ ICANS Institut de cancérologie Strasbourg Europe, Strasbourg
- ★ Centre Jean Perrin, Clermont-Ferrand
- ★ Institut du Cancer de Montpellier (ICM), Montpellier
- ★ Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- ★ Centre Oscar Lambret, Lille
- ★ Institut Bergonié, Bordeaux
- ★ Centre Antoine Lacassagne, Nice
- ★ Institut Godinot, Reims
- ★ Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy
- ★ Institut du Cancer – AP-HP. Université Paris-Saclay, Villejuif
- ★ Institut Sainte Catherine, Avignon

Germany

- ★ Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- ★ Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden
- ★ Charité Comprehensive Cancer Center, Berlin
- ★ Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt
- ★ Comprehensive Cancer Center München, Munich
- ★ Bayerisches Zentrum für Krebsforschung (BZKF), Erlangen

Greece

- ★ General Oncology Hospital of Athens "Saint Savvas", Athens
- ★ General Oncology Hospital of Pireaus Metaxa, Pireaus
- ★ Hellenic Cancer Federation -ELLOK, Athens

Hungary

- ★ Országos Onkológiai Intézet, Budapest
- ★ National Korányi Institute for Pulmonology, Budapest

Iceland

- ★ Landspítali, Reykjavík

Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont RCSI Cancer Centre, Dublin
- ★ HSE West North West, University of Galway Cancer Centre, Galway
- ★ Cork University Hospital/University College Cork, Cork
- ★ Mater Private Network, Dublin
- ★ The Mater Misericordiae University Hospital, Dublin
- ★ St Vincent's UCD Cancer Centre, Dublin
- ★ Mid-Western Cancer Centre, Limerick
- ★ Irish Cancer Society, Dublin

Italy

- ★ Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genoa
- ★ Istituto Europeo di Oncologia, Milan
- ★ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Naples

- ★ Istituto Nazionale Tumori Regina Elena, Rome
- ★ IRCCS Ospedale San Raffaele (OSR), Milan
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padua
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milan)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Turin)
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- ★ Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- ★ ASST Spedali Civili di Brescia (SCH), Brescia
- ★ Fondazione Poliambulanza, Brescia
- ★ Fondazione IRCCS Policlinico San Matteo, Pavia
- ★ IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- ★ Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
- ★ Istituto Dermatologico San Gallicano, Rome
- ★ Federazione italiana delle Associazioni di Volontariato in Oncologia (FAVO), Rome

Jordan

- ★ King Hussein Cancer Center, Amman

Latvia

- ★ Rīgas Austrumu klīniskā universitātes slimnīca, Riga
- ★ Paula Stradiņa Klīniskā universitātes slimnīca, Riga

Lebanon

- ★ Naef K Basile Cancer Institute at the American University of Beirut Medical Center, Beirut

Lithuania

- ★ National Cancer Institute, Vilnius
- ★ Vilnius University Hospital Santaros Klinikos, Vilnius
- ★ Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas

Luxembourg

- ★ Institut National du Cancer (INC), Strassen

Moldova

- ★ Public Health Institution Oncological Institute, Chisinau

Norway

- ★ Oslo Universitetssykehus (OUS), Oslo
- ★ Helse Bergen HF (Haukeland University Hospital), Bergen
- ★ Akershus University Hospital Trust, Lørenskog

Peru

- ★ Oncocenter Peru - SAC, Lima

Poland

- ★ Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw
- ★ Instytut Matki i Dziecka, Warsaw
- ★ Wielkopolskie Centrum Onkologii, Poznań

Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto
- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

Romania

- ★ Institutul Regional de Oncologie Iasi, Iasi
- ★ Asociatia Cancer Free Future (CFFA), Cluj-Napoca

Serbia

- ★ Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia

- ★ Biomedicinske centrum Slovenskej akadémie vied, Bratislava

Slovenia

- ★ Onkološki Inštitut Ljubljana, Ljubljana

Spain

- ★ Vall d'Hebron Barcelona Campus Hospitalari, Barcelona
- ★ Cancer Center Clinica Universidad de Navarra, Pamplona
- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- ★ Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)
- ★ Fundación Jiménez Díaz University Hospital, Madrid
- ★ Institut d'Oncologia de la Catalunya Sud Hospital Universitari Sant Joan de Reus, Reus
- ★ Hospital Universitario 12 de Octubre, Madrid
- ★ Clínic Barcelona Comprehensive Cancer Centre, Barcelona
- ★ Hospital Universitario La Paz, Madrid
- ★ Hospital Universitario Ramon Y Cajal, Madrid
- ★ Hospital Universitario Clínico San Carlos, Madrid
- ★ Hospital Clínico Universitario de Valencia (Departamento de Salud Clínico-Malvarrosa), Valencia
- ★ Hospital General Universitario Gregorio Marañón, Madrid
- ★ Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda
- ★ Centro Integral Oncológico Clara Campal, Madrid
- ★ Hospital Universitario Virgen de la Victoria, Málaga
- ★ La Princesa University Hospital, Madrid
- ★ Hospital Universitario y Politécnico La Fe, Valencia
- ★ Fundació de Gestió Sanitària de l'Hospital de La Santa Creu i Sant Pau - Campus Sant Pau – Puigvert, Barcelona

Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Uppsala University Hospital, Uppsala
- ★ Sahlgrenska University Hospital, Göteborg
- ★ Linköping Comprehensive Cancer Center, Linköping
- ★ Norrlands Universitetssjukhus, Umeå
- ★ University Hospital of Örebro - Örebro Comprehensive Cancer Centre, Örebro
- ★ Nätverket mot cancer, Stockholm

Switzerland

- ★ Comprehensive Cancer Center Zürich (CCCZ), Zurich

Tanzania

- ★ The Aga Khan Hospital, Dar es Salaam, Dar es Salaam

The Netherlands

- ★ OncoZON Cancer Network, Maastricht
- ★ Netherlands Cancer Institute, Amsterdam
- ★ Erasmus MC Cancer Institute, Rotterdam
- ★ Maastricht University Medical Centre+, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- ★ Rijnstate, Arnhem
- ★ Radboudumc Centrum voor Oncologie, Nijmegen
- ★ IKNL Integraal Kankercentrum Nederland, Utrecht

Turkey

- ★ Anadolu Sağlık Merkezi, Kocaeli
- ★ Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, İzmir
- ★ Türkiye Cancer Institute-TKE, Istanbul

Ukraine

- ★ RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv
- ★ National Cancer Institute, Kyiv

United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cancer Research UK Cambridge Centre, Cambridge
- ★ Velindre Cancer Service - part of Velindre University NHS Trust, Cardiff

Viet Nam

- ★ Bệnh viện K, Hanoi

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy

Maria Skłodowska - Curie National
Research Institute of Oncology
www.nio.gov.pl



Maria Skłodowska-Curie National Research Institute of Oncology (MSCI) is the largest and one of the most important comprehensive oncology centers in Central Europe. The Institute conducts therapeutic, research and development, educational, and organizational activities in oncology. Its main headquarters is located in Warsaw, with regional branches in Kraków and Gliwice. The entire institution employs over 5,800 people, including more than 1,300 doctors, 1,400 nurses, and over 220 research staff. In 2024 alone, the Warsaw headquarters of the National Institute of Oncology recorded over 100,000 hospitalizations, more than 300 major surgeries, and almost 500,000 outpatient visits.

Historically, the Institute originated from the Radium Institute established at the initiative of Marie Skłodowska-Curie in the 1920s. Destroyed during World War II and rebuilt afterward, it grew into a national leader in cancer treatment, research and epidemiology. In the 1950', the Cancer Control Program was developed, which encompassed the expansion of scientific research—both basic and clinical—along with cancer epidemiology and prevention, as well as the creation of an oncology network. A key element was the establishment of the Central (later National) Cancer Registry in 1952.

Cancer Prevention Center provides counseling, screening programs and education focused on reducing cancer risk and detecting disease at its earliest stages. It hosts prevention programs for colorectal, cervical, breast and skin cancers and participates in international initiatives such as the Nordic-European Initiative on Colorectal Cancer and the European Polyp Surveillance Trial. The Center operates in a purpose-built facility equipped with state-of-the-art technology and staffed by specialists trained in preventive oncology.



Clinically, the Institute provides comprehensive diagnostic and therapeutic services across organ-oriented departments staffed by highly trained specialists. Each department provides the full range of combined treatment, including surgery, radiotherapy and systemic therapy, offering unique opportunities for clinical research integrated with patient care. The Warsaw branch alone offers more than 700 beds and treats the largest number of cancer patients in the country.

The Institute conducts more than 600 clinical trials, including many early-phase studies carried out in the Early-Phase Clinical Trials Unit (EPU), the first such dedicated oncology facility in Poland. The EPU is equipped and staffed to conduct First-in-Human, proof-of-concept, dose-escalation, bioavailability and drug-interaction studies according to international standards.

The Institute holds the status of a reference center for the treatment of rare adult solid cancers as a member of EURACAN (European Reference Network on Rare Adult Solid Cancers), operating under the aegis of the European Commission. MSCI is also a member of the Organization of European Cancer Institutes (OECI). Its experts actively contribute to international oncology development efforts, cooperating with organizations such as ESMO, EORTC, ESTRO, ESSO, ESO, ASCO, IARC, EACR, and AACR, which enables the co-creation of European and global oncology care standards.

A major area of scientific activity includes research on genetic and epigenetic mechanisms responsible for cancer development. Projects focus on the role of epigenetics and microRNAs, identification of novel therapeutic targets, and analysis of genetic predisposition to cancers of the breast, thyroid, lung and large bowel. Other important fields of study include population-based assessments of individuals at increased genetic risk and the prevalence of hereditary cancer syndromes. The Institute also develops murine models to test novel targeted therapies. Molecular markers are studied for their diagnostic and prognostic value, especially in lymphomas, soft tissue sarcomas, gliomas, meningiomas, and cancers of the lungs, large bowel, ovaries and vulva. Additional work includes the detection of tumor cells in body fluids and development of genetic profiles for laboratory animals used in modeling.

In 2024, MSCI carried out over 60 research projects as part of the Thematic Scientific Research and Development Plan, as well as numerous projects funded from external sources, including the National Science Centre, the National Centre for Research and Development, the Medical Research Agency, the European Commission, and the U.S. National Institutes of Health. The Institute also plays a key role in educating medical professionals – it conducts specialization programs, postgraduate training, and operates a doctoral school. It supports the development of young scientists through scholarship and grant programs, ensuring knowledge transfer and a high level of professional competence. Additionally, the Institute hosts the Student Onco-Forum, the first organization of its kind in Poland run by medical students, which supports their scientific development and promotes oncology as a career path.

The Institute also plays a key role in educating medical professionals – it conducts specialization programs, postgraduate training, and operates a doctoral school. It supports the development of young scientists through scholarship and grant programs, ensuring knowledge transfer and a high level of professional competence. Additionally, the Institute hosts the Student Onco-Forum, the first organization of its kind in Poland run by medical students, which supports their scientific development and promotes oncology as a career path.

The Institute also plays a strategic role in Poland's healthcare system as the coordinator and implementer of the National Oncology Strategy and as the National Monitoring Center for the implementation of the National Oncology Network. The National Cancer Registry, which is the main source of epidemiological data on cancer in Poland, also operates within the Institute. Furthermore, the Institute develops and implements national diagnostic and therapeutic guidelines in oncology.

The vision of The Institute is to further strengthen its position as the national leader in oncology and to become a leading oncology center in Central and Eastern Europe, through the integration of clinical, scientific, and educational activities in line with the highest international standards.

Oncology Days Warsaw - Timetable

Oncology Days Warsaw - Timetable

	16 June 2026	17 June 2026	
MORNING	A&D Board Meeting 11.00 – 13.00 <i>(Restricted to A&D Board Members)</i>	Accreditation & Designation Session 1 Current developments and excellent practices from our accredited centres 08.45 – 10.45	
		Coffee Break	
		Accreditation & Designation Session 2 More excellent practices from our accredited centres 11.00 – 13.00	
	Lunch	Lunch	
AFTERNOON	OECI Board & Extended Board Meeting 14.00 – 18.00 <i>(Restricted to OECI Board and Extended Board Members)</i>	OECI for Patients WG Session 14.00 – 16.00	Cancer Economics WG Session 14.00 – 16.00
		Coffee Break	
		EUonQoL Session 16.30 – 18.30	Biobanking, Personalised Medicine and AI 16.30 – 18.30
EVENING	Board Dinner	19.30 - Social Event	

18 June 2026		19 June 2026		
Scientific Conference Session 1 New technology on Precision Prevention 08.45 – 10.45		General Assembly Administrative Session & Ceremony A&D Certificates 08.30 – 10.00 (Vote restricted to Delegates of OECD Full Members present or represented)		MORNING
Coffee Break		Coffee Break		
Scientific Conference Session 2 National Cancer Networks 11.00 – 13.00		Open Discussion with Members & close of the 2026 G.A. 10.15 – 12.30 (Restricted to Delegates of OECD Members)		
Lunch		Lunch		
OECD Young Network Session 14.00 – 16.00	OECD A&D Auditors Session 14.00 – 16.00			AFTERNOON
Coffee Break				
CCI4EU – Final Report and Expectations on Capacity Building Session 16.30 – 17.30				
OECD Participation to 2026 and 2027 EC calls 17.30 – 18.30				
20.00 Gala Dinner Kubicki Arcades of the Royal Castle				EVENING

Accreditation and Designation Session 1

Current developments and excellent practices from our accredited centres

In this session we give a brief overview of the state of play of the A&D programme, outlining the growth and development of the programme. We focus particularly on the accreditation of cancer networks which are an important growth area in Europe, in terms of cancer structures to deliver consistent high quality. We then continue with a selection of excellent practices from our accredited centres in areas of diagnosis and treatment. These have been specially selected by the A&D Board from strengths identified by audit teams from the accreditation process, and then documented with evidence of impact by the centres.

June 17

08.45 - 10.45

Accreditation and Designation Session 2

More excellent practices from our accredited centres

In this session we focus on a selection of excellent practices from our accredited centres. These have been specially selected by the A&D Board from strengths identified by audit teams from the accreditation process, and then documented with evidence of impact by the centres. These excellent practices are in all areas of the standards, from governance to patient empowerment, treatment to research, prevention to survivorship, early detection to education.

June 17

11.00 - 13.00

Cancer Economics WG Session

The session of the OECI Working Group on Health/Cancer Economics will be focusing on topics related to the new WG-strategy 2026-2028. This will for instance focus on input from OECI centers in to Real-World-Data based efficiency- and HTA studies.

We will present the results on a Delphi study on how to proceed in this field and a case study illuminating the importance.

Further two cases will clarify the opportunities of centers having a HTA unit within or close by their organisation in bringing relevant innovations swiftly to patients.

Lastly we foresee input from a renowned speaker on the status and consequences of geopolitical developments on costs and pricing of oncology medicines in the coming years.

June 17

14.00 - 16.00

OECI for Patients WG

Advancing meaningful Patient and Public Involvement (PPI) in global cancer care and research

The session aims at strengthening knowledge on how PPI can be effectively implemented in cancer care. It will present findings from a multi-centre qualitative study conducted in line with the OECI Accreditation and Designation Manual, specifically the chapter on patient involvement and empowerment. Drawing on the perspectives of PPI leads, the study explores how OECI centres understand, practice and promote PPI. Consequently, key enablers and barriers are identified.

Building on these findings, the session will include an interdisciplinary panel gathering cancer centre directors, PPI coordinators, clinicians, and patient representatives. The panel will reflect on the study results, share best practices, and discuss pathways for strengthening PPI implementation across the network.

By the end of the session participants will identify priority actions for advancing meaningful, equitable, and sustainable PPI within OECI centres.

June 17

14.00 - 16.00

Conference Room:

OECI2026 ONCOLOGY DAYS

EUonQoL Session



June 17

16.30 - 18.30

This session will present the latest developments of the EUonQoL-kit Version 3, the innovative European toolkit designed to measure and monitor the Quality of Life of living with and beyond cancer. The discussion will focus on the alternative structures of the toolkit and their potential future applications across diverse clinical, research, and policy contexts. A key highlight will be the introduction of the new e-platform developed to enable spontaneous and real-time data collection through the EUonQoL-kit, creating opportunities for dynamic patient engagement and improved data integration across cancer centres and healthcare systems.

The session will also explore the implementation strategy for the EUonQoL-kit, including approaches to harmonisation, validation, and uptake within the OECI network and beyond. Special attention will be given to policy outreach and dissemination activities designed to ensure that EUonQoL outcomes inform European and national cancer policies, with the goal of improving patient-centred care practices.

Finally, the session will connect with the Quality of Life – Patient Centred Care (QoL-PCC) Cluster, highlighting collaborative initiatives aimed at aligning methodologies, sharing data, and promoting the use of QoL measures as a cornerstone of comprehensive cancer care. Through presentations and open discussion, this session will outline how EUonQoL is shaping the future of quality of life monitoring, research translation, and policy integration in the European cancer landscape.

Biobanking, Personalised Medicine and AI

Session to be confirmed

June 17

16.30 - 18.30



Oncology Days

June 2027 Dublin, Ireland

GENERAL ASSEMBLY
SCIENTIFIC CONFERENCES
AND RELATED EVENTS



Organisation
of European
Cancer Institutes

European Economic
Interest Grouping



DEVELOPING
THE FUTURE IN
COMPREHENSIVE
CANCER CARE

Session 1

New Technology in Primary and Secondary Prevention

08.45 - 10.45

This session explores innovative, technology-driven approaches to primary and secondary prevention, from genomics and AI-assisted early detection to population-based HPV vaccination programmes. Experts from leading OECD institutes will discuss how data, digital tools, and precision prevention can reshape European cancer networks and policies.

08.45 Opening and Introduction

Chairpersons: **Giovanni Apolone** and **Śławomir Blamek**

09.00 European Code Against Cancer (ECAC5) in Everyday Practice Low-Cost, Effective Micro-Interventions OECD Institutes Can Deploy

09.15 Closing the Gap Fast – Digital Recalls and Other Solutions to Increase HPV Vaccination Coverage

09.30 The Influence of Artificial Intelligence in Oncology Multidisciplinary Teams Decisions

09.45 Genetics for the Few, Prevention for the Many – A Pragmatic Playbook for OECD

10.00 Reaching the Next Generation – Modern Communication Tools to Shape Healthy Behaviors Among Young People

10.20 Panel Discussion: Scaling Prevention Across Europe From Awareness to System Change

Led by **Śławomir Blamek** and **Giovanni Apolone**

Panelists *All session speakers*

10.45 Coffee Break

Session 2

National Cancer Networks Networking in Oncology: National Models of Collaboration and Excellence in Europe

11.00 - 13.00

This session showcases successful national oncology network models across Europe - integrating research, quality assurance, patient pathways and data ecosystems. Speakers will present how coordinated national frameworks enhance outcomes and what lessons can guide emerging networks in Central and Eastern Europe.

11.00 Opening and Introduction

Chairpersons: **Simon Oberst** and **Beata Jagielska**

11.20 Patient Pathways and Coordination of Cancer Care – The Dutch Experience

11.35 Accreditation and Quality Assurance in Oncology – The Italian Model

11.50 Patient Involvement and Shared Decision-Making – Lessons from Sweden

12.05 Building a National Oncology Network in Poland – Challenges and Opportunities in the CEE Region

12.20 The German Oncology Network – Integration Across Hospitals and Comprehensive Cancer Centres

12.35 Panel Discussion

Led by **Simon Oberst** and **Beata Jagielska**

Panelists *All session speakers*

OECI Young Network Session

At the first session at the OECI Oncology Days led by the Young Board, we will introduce our mission, ongoing initiatives, and our ambitions for the coming years. The focus will be on how junior professionals can actively participate and benefit from our activities across the network.

By emphasizing the value of collaborative activities, including twinning and research grant programmes, we aim to demonstrate how the Young Board can serve as a catalyst for both scientific/clinical career development and improved patient care. The session will include an interactive aspect, where participants are encouraged to share their needs, expectations, and ideas to build the next phase of our network, together.

Shaping the Future Together: The Young Board's Vision, Actions & Opportunities

Session organized by the Young Board

Chairpersons: Evy Lobbestael and Ilkka Liikanen

June 18

14.00 - 16.00

OECI A&D Auditors Session

This is a session restricted to auditors and A&D programme staff, and for those cancer centres interested in joining the A&D programme. In the session we will outline current developments in the A&D programme, issues in auditing, and what we can do to improve our processes and data flows.

June 18

14.00 - 16.00

CCI4EU Final Report and Expectations on Capacity Building Session CSA Session

CCI4EU (Comprehensive Cancer Infrastructures for the EU) concludes in April 2026. In this session we outline the successes and impacts of the 3-year action, and we describe the main interventions in capacity building and their impact: the Deep Dive consultancy interventions; the regional conferences; the online courses, and the observerships. We also describe the Maturity Model adopted, and the manner of evaluating impact through a Global Efficacy Score. We hear some feedback from the CCIs, and then outline the requirements to sustain the progress achieved in the Comprehensive Cancer Infrastructures.

June 18

16.30 - 17.30

OECI Participation in the 2026 and 2027 European Commission Calls

This session will outline the strategic approach and planned activities of OECI in relation to the 2026 and 2027 European Commission (EC) funding calls. It will present an overview of relevant Horizon Europe work programmes and other EU initiatives that align with OECI's mission to enhance cancer research, innovation, and care quality across Europe. The session will focus on identifying key thematic areas for participation, fostering collaborative opportunities among OECI members, and strengthening the network's engagement in EU-funded projects. Attendees will gain insights into proposal preparation processes, partnership building, and the mechanisms through which OECI can contribute to and benefit from the forthcoming EC calls, reinforcing its role as a leading actor in the European cancer research and care ecosystem.

June 18

17.30 - 18.30

Draft Agenda

08.00 **Registration**

08.15 **Opening**

General Assembly Constitution, welcome and approval of the Agenda
Giovanni Apolone

08.30 **Administrative Session**

Chairperson: Giovanni Apolone

Point 1: Approval of the General Assembly Minutes of 13 June 2025

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Giovanni Apolone

Point 2: Approval of the Financial Statement 2025 and discharge to the Board

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Diego Pazienza

Point 3: OECI 2025 Provisional Budget

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Alfredo Budillon

Point 4: OECI Board composition for the coming years and renewal mandate for three Elected Members

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Giovanni Apolone

Point 5: Hand-over of the 2023-2026 Presidency, and transfer of powers to the 2026-2029 Presidency

(vote not requested)

Giovanni Apolone and Iwona Ługowska

Point 6: New applications/resignation to the OECI membership, proposal of dismissals and requests of exemption from membership fee payment

(vote requested: for full membership and fee exemption - decision to be taken by unanimity of the OECI Full Members present or represented; for dismissal - decision to be taken by 2/3 of the OECI Full Members present or represented; for associate membership Type A-B-C - decision to be taken by simple majority of the OECI Full Members present or represented; no voting for membership withdrawals).

Claudio Lombardo

Point 7: Proposals for the Oncology Days 2027 and for the coming years
Iwona Ługowska and John Kennedy

10.45 **Coffee Break**

CEREMONY FOR THE DELIVERY OF THE OECI A&D CERTIFICATES June 2025-June 2026

Iwona Ługowska and Mef Nilbert

**ACCREDITATION
AND
DESIGNATION
PROGRAMME**



Open Discussion with Members & Close of the 2025 General Assembly

June 19

10.15 - 12.30

11.00 **Scientific Session**

The OECI Presidential Strategy 2026 - 2029

Iwona Ługowska

11.15 **OECI Academy**

Per Anders Sandström

11.30 **OECI Young Network**

Vince Kornél Grolmusz and Rebecca Amet

11.45 **OECIWORLD**

Thierry Philip

12.00 **Open discussion with the Members**

Chairpersons: Iwona Ługowska and Vice President

12.45 **Closure of the 2026 OECI General Assembly**

13.00 **Lunch**

Warsaw

Warsaw is a dynamic and fast-growing European capital. It is the political, economic and cultural centre of Poland. It is often referred to as the “Phoenix City” because it rose from near-total destruction during the II World War to become a major European centre of culture, science, and business.

June is one of the best months to visit Warsaw, as the city enjoys warm and pleasant weather. Average daytime temperatures range from 20°C to 24°, with longer daylight hours—up to 17 hours of light. Occasional rain showers can occur, but they are usually brief. Parks and river boulevards are in full bloom, and locals spend time outdoors enjoying the mild evenings. It's a perfect time for sightseeing, outdoor cafés, and festivals.



OECD 2026 Gala Dinner

June 18 - 20.00 Hrs

The Gala Dinner of Oncology Days 2026 will be hosted at the Kubicki Arcades in Warsaw, an elegant and historic venue forming part of the Royal Castle complex. Designed in the early 19th century by architect Jakub Kubicki, the arcades originally supported the castle gardens and have since been carefully restored to serve as a distinctive space for cultural and formal events. Situated at the foot of the Royal Castle, between the UNESCO-listed Old Town and the picturesque Vistula River escarpment, the Kubicki Arcades offer a unique combination of history, charm, and a welcoming atmosphere—an ideal setting for our special evening.



Hotels and logistics

The conference will take place in the very city center of Warsaw, with convenient access to hotels, public transport, and major attractions. We recommend booking flights to Warsaw Chopin Airport (WAW), which is the closest and most convenient airport for reaching the city center. From the airport, you can get to downtown Warsaw in several ways:

- Train (SKM or Koleje Mazowieckie) – Direct trains run from the airport to the Central Railway Station; the journey takes about 20–25 minutes.
- Bus – Several city bus lines connect the airport with central Warsaw; travel time is roughly 30 minutes depending on traffic.
- Taxi or Ride-hailing services (Bolt, Uber, FreeNow) – Taxis are available directly outside the terminal; the ride to the center typically takes 20–30 minutes.





THE OECD 2026 INTERNATIONAL SCIENTIFIC COMMITTEE

Presidents

Giovanni Apolone and Iwona Lugowska

Members

Rebecca Amet , Giovanni Apolone, Sławomir Blamek, Christian Brandts, Jean-Benoît Burrión, Alfredo Budillon, Maja Cemažar, Cinzia Brunelli, Olli Carpén, Steven le Gouill, Vince Kornél Grolmusz, Beata Jagielska, Claudio Lombardo, Iwona Lugowska, Mef Nilbert, Delia Nicoara, Simon Oberst, Júlio Manuel Ramos Maiade Oliveira, Thierry Philip, Janusz Ryś, Per Anders Sandström, Jacqueline M.L. Stouthard, Josep Tabernero Caturla, Wim H. van Harten

THE OECD 2026 ONCOLOGY DAYS SECRETARIATS

GENOA: Daniela Garbarino, Diana Kochegarova, Alex White

BRUSSELS: Roxana Plesoianu

MILAN: Eleonora De Palo

WARSAW: Agnieszka Janowska

OECD 2026 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo

oecl@oecl.eu - www.oecl.eu



In collaboration with:

Maria Skłodowska-Curie

**National Research
Institute of Oncology**